Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.234 EUR | -2.22% | -5.08% | -9.93% |
Jun. 03 | Transgene: first patient in phase II study | CF |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Sales 2024 * | 39.2M 42.1M | Sales 2025 * | 49.2M 52.84M | Capitalization | 125M 134M |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.04M | Net income 2025 * | -21M -22.55M | EV / Sales 2024 * | 3.7 x |
Net Debt 2024 * | 20.2M 21.7M | Net Debt 2025 * | 42.1M 45.22M | EV / Sales 2025 * | 3.39 x |
P/E ratio 2024 * |
-8.23
x | P/E ratio 2025 * |
-5.61
x | Employees | 141 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.42% |
Latest transcript on Transgene
1 day | -2.22% | ||
1 week | -5.08% | ||
Current month | -0.48% | ||
1 month | -8.46% | ||
3 months | +5.29% | ||
6 months | -13.10% | ||
Current year | -9.93% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
Director/Board Member | 63 | 04-12-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 1.234 | -2.22% | 15,849 |
24-06-10 | 1.262 | -3.07% | 29,797 |
24-06-07 | 1.302 | 0.00% | 10,617 |
24-06-06 | 1.302 | +0.15% | 10,244 |
24-06-05 | 1.3 | 0.00% | 29,887 |
Real-time Euronext Paris, June 11, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.93% | 137M | |
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+1.05% | 13.56B | |
+25.87% | 11.59B |
- Stock Market
- Equities
- TNG Stock